←back to thread

Cost of developing new drugs may be lower than industry claims: trial

(www.theguardian.com)
275 points swores | 1 comments | 25 Apr 24 12:25 UTC | HN request time: 0.336s | source
Show context
tompccs ◴[26 Apr 24 20:48 UTC] No.40174095[source]▶
You can't compare running a clinical trial for a drug targeting a communicable disease in the developing world to trials for treatments of complex diseases in rich countries where you need serology, histopathology and radiological endpoints.

Worth noting as well that J&J have shut down their entire division in communicable diseases because it was so unprofitable for them.

(Source: I work in this industry)

replies(3): >>40174444 #>>40174571 #>>40176425 #
thomassmith65 ◴[26 Apr 24 21:21 UTC] No.40174444[source]▶
Was it 'unprofitable' as in 'losing money', or 'unprofitable' as in 'not worth the time'? If it's the latter, I don't have enough information about the rest of J&J to draw any conclusions.
replies(1): >>40174593 #
s1artibartfast ◴[26 Apr 24 21:36 UTC] No.40174593[source]▶
Financially, they are the same.

If you can make more money by not doing X, than doing X, it doesnt matter.

replies(4): >>40174875 #>>40175414 #>>40176392 #>>40176606 #
interstice ◴[26 Apr 24 22:12 UTC] No.40174875[source]▶
That rules out just about any non regulated altruism. Eg open source
replies(2): >>40174933 #>>40176323 #
1. s1artibartfast ◴[26 Apr 24 22:18 UTC] No.40174933[source]▶
Charitable donations and altruism are outside the scope of financial analysis.

You can donate time or money even if you are running a loss in real, nominal, or opportunity costs.